Verastem Inc reports results for the quarter ended June 30 - Earnings Summary
08/08/2025 04:12
Verastem Inc VSTM.OQ reported a quarterly adjusted loss of 62 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of nine analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from -99 cents to -56 cents per share. Revenue fell 78.6% to $2.14 million from a year ago; analysts expected $1.12 million. Verastem Inc's reported EPS for the quarter was a loss of 62 cents. Verastem Inc shares had risen by 37.8% this quarter and gained 10.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 6.8% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Verastem Inc is $14.00, about 59.9% above its last closing price of $5.62 This summary was machine generated from LSEG data August 8 at 03:11 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.74 | -0.62 | Beat |
| Mar. 31 2025 | -0.71 | -0.79 | Missed |
| Dec. 31 2024 | -0.81 | -1.33 | Missed |
| Sep. 30 2024 | -0.74 | -0.60 | Beat |